id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1318-0126,FDA,FDA-2014-D-1318,"Testimony from Daniel Fisher, MD, PhD",Other,Testimony,2016-02-22T05:00:00Z,2016,2,2016-02-22T05:00:00Z,,2016-02-22T21:39:28Z,,0,0,0900006481e7c2a7
FDA-2014-D-1318-0002,FDA,FDA-2014-D-1318,"Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff",Other,Guidance,2015-12-29T05:00:00Z,2015,12,2015-12-29T05:00:00Z,,2024-11-11T21:19:55Z,,1,0,0900006481dd91f1
FDA-2014-D-1318-0001,FDA,FDA-2014-D-1318,"Electroconvulsive Therapy Devices for Class II Intended Uses: Draft Guidance for Industry, Clinicians, and FDA Staff; Availability",Notice,Notice of Availability,2015-12-29T05:00:00Z,2015,12,2015-12-29T05:00:00Z,2016-03-29T03:59:59Z,2016-03-29T04:00:44Z,2015-32591,0,0,0900006481dd7b15